Literature DB >> 17200374

Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats.

Nanjoo Suh1, Shiby Paul, Xingpei Hao, Barbara Simi, Hang Xiao, Agnes M Rimando, Bandaru S Reddy.   

Abstract

PURPOSE: Epidemiologic studies have linked the consumption of fruits and vegetables to reduced risk of several types of cancer. Laboratory animal model studies have provided evidence that stilbenes, phenolic compounds present in grapes and blueberries, play a role in inhibiting the risk of certain cancers. Pterostilbene, a naturally occurring stilbene from blueberries, was tested for its preventive activity against colon carcinogenesis. EXPERIMENTAL
DESIGN: Experiments were designed to study the inhibitory effect of pterostilbene against the formation of azoxymethane-induced colonic aberrant crypt foci (ACF) preneoplastic lesions in male F344 rats. Beginning at 7 weeks of age, rats were treated with azoxymethane (15 mg/kg body weight s.c., once weekly for 2 weeks). One day after the second azoxymethane treatment, rats were fed experimental diets containing 0 or 40 ppm of pterostilbene. At 8 weeks after the second azoxymethane treatment, all rats were sacrificed, and colons were evaluated for ACF formation and for inhibition of inducible nitric oxide synthase (iNOS) and proliferating cell nuclear antigen. Effects on mucin MUC2 were also determined.
RESULTS: Administration of pterostilbene for 8 weeks significantly suppressed azoxymethane-induced formation of ACF (57% inhibition, P < 0.001) and multiple clusters of aberrant crypts (29% inhibition, P < 0.01). Importantly, dietary pterostilbene also suppressed azoxymethane-induced colonic cell proliferation and iNOS expression. Inhibition of iNOS expression by pterostilbene was confirmed in cultured human colon cancer cells.
CONCLUSIONS: The results of the present study suggest that pterostilbene, a compound present in blueberries, is of great interest for the prevention of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200374     DOI: 10.1158/1078-0432.CCR-06-1528

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  Genetic polymorphisms in nitric oxide synthase genes modify the relationship between vegetable and fruit intake and risk of non-Hodgkin lymphoma.

Authors:  Xuesong Han; Tongzhang Zheng; Qing Lan; Yaqun Zhang; Briseis A Kilfoy; Qin Qin; Nathaniel Rothman; Shelia H Zahm; Theodore R Holford; Brian Leaderer; Yawei Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

2.  In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.

Authors:  Shiby Paul; Cassia S Mizuno; Hong Jin Lee; Xi Zheng; Sarah Chajkowisk; John M Rimoldi; Allan Conney; Nanjoo Suh; Agnes M Rimando
Journal:  Eur J Med Chem       Date:  2010-05-15       Impact factor: 6.514

3.  2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice.

Authors:  Haitao Li; William Ka Kei Wu; Zhi Jie Li; Kam Ming Chan; Clover Ching Man Wong; Cai Guo Ye; Le Yu; Joseph Jao Yiu Sung; Chi Hin Cho; Mingfu Wang
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.

Authors:  Nanjoo Suh; Bandaru S Reddy; Andrew DeCastro; Shiby Paul; Hong Jin Lee; Amanda K Smolarek; Jae Young So; Barbara Simi; Chung Xiou Wang; Naveena B Janakiram; Vernon Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-15

5.  Pterostilbene inhibits pancreatic cancer in vitro.

Authors:  Patrick W Mannal; Juile A Alosi; John G Schneider; Debbie E McDonald; David W McFadden
Journal:  J Gastrointest Surg       Date:  2010-02-06       Impact factor: 3.452

Review 6.  Beyond Conventional Medicine - a Look at Blueberry, a Cancer-Fighting Superfruit.

Authors:  Kristoffer T Davidson; Ziwen Zhu; Dean Balabanov; Lei Zhao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Pathol Oncol Res       Date:  2017-12-28       Impact factor: 3.201

7.  Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats.

Authors:  Izet M Kapetanovic; Miguel Muzzio; Zhihua Huang; Thomas N Thompson; David L McCormick
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-30       Impact factor: 3.333

8.  Fluorinated N,N-dialkylaminostilbenes for Wnt pathway inhibition and colon cancer repression.

Authors:  Wen Zhang; Vitaliy Sviripa; Liliia M Kril; Xi Chen; Tianxin Yu; Jiandang Shi; Piotr Rychahou; B Mark Evers; David S Watt; Chunming Liu
Journal:  J Med Chem       Date:  2011-02-03       Impact factor: 7.446

9.  Lack of efficacy of blueberry in nutritional prevention of azoxymethane-initiated cancers of rat small intestine and colon.

Authors:  Frank A Simmen; Julie A Frank; Xianli Wu; Rijin Xiao; Leah J Hennings; Ronald L Prior
Journal:  BMC Gastroenterol       Date:  2009-09-16       Impact factor: 3.067

10.  A stress-inducible resveratrol O-methyltransferase involved in the biosynthesis of pterostilbene in grapevine.

Authors:  Laure Schmidlin; Anne Poutaraud; Patricia Claudel; Pere Mestre; Emilce Prado; Maria Santos-Rosa; Sabine Wiedemann-Merdinoglu; Francis Karst; Didier Merdinoglu; Philippe Hugueney
Journal:  Plant Physiol       Date:  2008-09-17       Impact factor: 8.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.